With BioNTech’s vaccine candidate, hope for more normalcy rises. This means that concerts, theater and cinema visits can somehow be back on the consumer’s agenda. This is a good development for companies like CTS Eventim. However, there should still be restrictions at least until the end of the first half of 2021. Orders for 2022 could then run more normally again.
The analysts at DZ Bank believe that CTS Eventim will not return to the level of 2019 until 2024. At that time there were earnings per share of 1.38 euros. In 2020, the experts forecast a loss per paper of 1.24 euros. In 2021 there should be an increase of 0.21 euros.
The experts stick to the sell recommendation for the shares of CTS Eventim. The price target remains at EUR 33.00.
The share has recently increased significantly. This results in a PER 2021e of 241. The risk-reward ratio is unattractive.
The shares of CTS Eventim lose 1.4 percent in the evening to 49.42 euros. A week ago the share was still around 41 euros.